{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 54,
  "pageCount": 105,
  "prevPage": 53,
  "nextPage": 55,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 36,
  "notes": "The slide demonstrates synergistic efficacy of KT-413 across three different combination therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/54",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-54",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Tumor volume over time with BTK inhibitor",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a66d5a7-7777-4fb9-9257-834cb61e8217",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.36,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Tumor volume over time with BCL-2 inhibitor",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b9538a8-975f-4794-9956-2043b1561e14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.67,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Tumor volume over time with Rituxan",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de6c1968-4164-4ef0-ab49-703963db7495",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.67,
        "y": 0.6
      },
      "kind": "list",
      "text": "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with Rituxan",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1201c256-650c-4c04-9388-86842042d66c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.36,
        "y": 0.6
      },
      "kind": "list",
      "text": "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with the BCL-2 inhibitor, Venetoclax",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ddd4bb0-f447-43bc-8ce6-7c9c6b6b7557",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "KT-413 administered on intermittent schedules leads to strong regressions in combination with the BTK inhibitor Ibrutinib",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8012cdb-b2fd-401c-81a1-3b7d76486524",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.85
      },
      "kind": "title",
      "text": "Data support potential for KT-413 in combination in earlier lines of therapy",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0ec04e8-5586-42c9-b8df-002b00cfccca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-413 Has Strong Activity in Combination in MYD88MT OCI-Ly10 Xenografts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "602dadf5-c33e-4a7a-9f83-685f7a5ff27d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "8abcba8c-a127-4a9d-ade7-44b9ded10705",
      "evidence": "title/action-title: Data support potential for KT-413 in combination in earlier lines of therapy",
      "confidence": 0.7
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "6c5ae8ed-b8f1-4866-acc8-aaae5f0b08be",
      "evidence": "chart/line: Tumor volume over time with BCL-2 inhibitor",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}